There are currently 967 clinical trials in Salt Lake City, Utah looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Utah, Huntsman Cancer Institute/University of Utah, Huntsman Cancer Institute and LDS Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors
NCT03276676
Recruiting
The hypothesis of this exploratory clinical trial in patients with high-grade a primary brain tumor who receive chemoradiation is that the PET imaging agents [18F]Fluciclovine and/or [18F]FLT will be a better predictor of tumor response than standard MRI based brain tumor response criteria. When used in conjunction, the two PET agents may be better able to predict tumor aggressiveness and thus overall survival than the use of individual-tracer PET biomarkers. This may eventually lead to improved... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Brain Tumor
Register for Updates
Pyruvate Kinase Deficiency Global Longitudinal Registry
NCT03481738
Recruiting
This study is an observational (ie, noninterventional), longitudinal, multicenter, global registry for patients with pyruvate kinase (PK) deficiency, a rare nonspherocytic hemolytic anemia. This Registry will be open for enrollment for 7 years and all enrolled participants will be followed prospectively for a minimum of 2 years, and up to 9 years. Data will be collected from participating Registry Physicians, participants, and, where appropriate, parents/guardians who have provided informed co... Read More
Gender:
All
Ages:
All
Trial Updated:
06/12/2024
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Pyruvate Kinase Deficiency
Register for Updates
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
NCT03598257
Recruiting
This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. It is not yet known... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: University of Utah Sugarhouse Health Center, Salt Lake City, Utah +1 locations
Conditions: Breast Inflammatory Carcinoma
Register for Updates
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer
NCT04109729
Recruiting
This is an open label, prospective, trial that begins with a phase Ib safety run-in followed by a phase II expansion cohort.
Gender:
Male
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515
Recruiting
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Utah Cancer Specialists, Salt Lake City, Utah
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
NCT04576156
Recruiting
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory to Janus Kinase (JAK)-Inhibitor treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Utah Cancer Specialists, Salt Lake City, Utah
Conditions: Myelofibrosis
Register for Updates
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06253221
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
06/11/2024
Locations: Local Institution - 0003, Salt Lake City, Utah
Conditions: Cardiomyopathy, Hypertrophic
Register for Updates
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
NCT04071223
Recruiting
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and sympto... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
Register for Updates
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260
Recruiting
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
06/11/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
NCT05769608
Recruiting
a Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat (an aldosterone synthase inhibitor), administered on a background of a standardized anti-hypertensive (AHT) medication regimen, in subjects with uncontrolled and/or treatment-resistant hypertension.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: The University of Utah, Salt Lake City, Utah
Conditions: Hypertension
Register for Updates
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/11/2024
Locations: Research Site, Salt Lake City, Utah
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT03816345
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
Register for Updates